Although previous studies explored the association of HER-2 expression or TILs alone with BC prognosis [22,23], the novelty of this study lies in the integration of HER-2 expression, TIL levels, and various clinical pathological features into a unified analytical framework, revealing the synergistic relationship between these factors. The gene discussed is ERBB2; the disease is breast cancer.